Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, Califano A, Yamashiro DJ.

Oncogene. 2018 Jun 7. doi: 10.1038/s41388-018-0326-9. [Epub ahead of print]

PMID:
29880876
2.

Erythema nodosum arising during everolimus therapy for tuberous sclerosis complex.

Galligan ER, Fix L, Levin LE, Imundo L, Yamashiro DJ, Garzon MC.

Pediatr Dermatol. 2018 Jul;35(4):e235-e236. doi: 10.1111/pde.13524. Epub 2018 May 16.

PMID:
29766561
3.

A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome-Review of the Literature.

Kadakia N, Lobritto SJ, Ovchinsky N, Remotti HE, Yamashiro DJ, Emond JC, Martinez M.

Front Pediatr. 2017 Jun 7;5:114. doi: 10.3389/fped.2017.00114. eCollection 2017.

4.

Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL.

Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6.

5.

A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.

Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Glade Bender JL, Kung AL.

Genome Med. 2016 Oct 31;8(1):116. doi: 10.1186/s13073-016-0366-0.

6.

HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma.

Tavana O, Li D, Dai C, Lopez G, Banerjee D, Kon N, Chen C, Califano A, Yamashiro DJ, Sun H, Gu W.

Nat Med. 2016 Oct;22(10):1180-1186. doi: 10.1038/nm.4180. Epub 2016 Sep 12.

7.

High-Dose, Single-Fraction Irradiation Rapidly Reduces Tumor Vasculature and Perfusion in a Xenograft Model of Neuroblastoma.

Jani A, Shaikh F, Barton S, Willis C, Banerjee D, Mitchell J, Hernandez SL, Hei T, Kadenhe-Chiweshe A, Yamashiro DJ, Connolly EP.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1173-80. doi: 10.1016/j.ijrobp.2015.12.367. Epub 2015 Dec 29.

PMID:
26907918
8.

Inhibition of Notch promotes liver metastasis.

Banerjee D, Kadenhe-Chiweshe A, Yamashiro DJ.

Aging (Albany NY). 2015 Sep;7(9):603-4. No abstract available.

9.

Notch suppresses angiogenesis and progression of hepatic metastases.

Banerjee D, Hernandez SL, Garcia A, Kangsamaksin T, Sbiroli E, Andrews J, Forrester LA, Wei N, Kadenhe-Chiweshe A, Shawber CJ, Kitajewski JK, Kandel JJ, Yamashiro DJ.

Cancer Res. 2015 Apr 15;75(8):1592-602. doi: 10.1158/0008-5472.CAN-14-1493. Epub 2015 Mar 5.

10.

Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis.

Hernandez SL, Banerjee D, Garcia A, Kangsamaksin T, Cheng WY, Anastassiou D, Funahashi Y, Kadenhe-Chiweshe A, Shawber CJ, Kitajewski JK, Kandel JJ, Yamashiro DJ.

Vasc Cell. 2013 Sep 25;5(1):17. doi: 10.1186/2045-824X-5-17.

11.

A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties.

Ma TC, Langley B, Ko B, Wei N, Gazaryan IG, Zareen N, Yamashiro DJ, Willis DE, Ratan RR.

Neurobiol Dis. 2013 Jan;49:13-21. doi: 10.1016/j.nbd.2012.08.016. Epub 2012 Aug 27.

12.

A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.

Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR.

Clin Cancer Res. 2012 Sep 15;18(18):5081-9. Epub 2012 Jul 12.

13.

A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma.

Cheng WY, Kandel JJ, Yamashiro DJ, Canoll P, Anastassiou D.

PLoS One. 2012;7(4):e34705. doi: 10.1371/journal.pone.0034705. Epub 2012 Apr 6.

14.

Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.

Sirsi SR, Flexman ML, Vlachos F, Huang J, Hernandez SL, Kim HK, Johung TB, Gander JW, Reichstein AR, Lampl BS, Wang A, Hielscher AH, Kandel JJ, Yamashiro DJ, Borden MA.

Ultrasound Med Biol. 2012 Jun;38(6):1019-29. doi: 10.1016/j.ultrasmedbio.2012.01.014. Epub 2012 Mar 16.

15.

Monitoring early tumor response to drug therapy with diffuse optical tomography.

Flexman ML, Vlachos F, Kim HK, Sirsi SR, Huang J, Hernandez SL, Johung TB, Gander JW, Reichstein AR, Lampl BS, Wang A, Borden MA, Yamashiro DJ, Kandel JJ, Hielscher AH.

J Biomed Opt. 2012 Jan;17(1):016014. doi: 10.1117/1.JBO.17.1.016014.

16.

Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo.

Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, Yamashiro DJ, Kandel JJ.

BMC Cancer. 2011 Dec 30;11:529. doi: 10.1186/1471-2407-11-529.

17.

Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

Glade Bender J, Yamashiro DJ, Fox E.

Oncologist. 2011;16(11):1614-25. doi: 10.1634/theoncologist.2011-0148. Epub 2011 Oct 31. Review.

18.

Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.

Fisher JC, Gander JW, Haley MJ, Hernandez SL, Huang J, Chang YJ, Johung TB, Guarnieri P, O'Toole K, Yamashiro DJ, Kandel JJ.

Vasc Cell. 2011 Oct 6;3:22. doi: 10.1186/2045-824X-3-22.

19.

Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors.

Sirsi SR, Hernandez SL, Zielinski L, Blomback H, Koubaa A, Synder M, Homma S, Kandel JJ, Yamashiro DJ, Borden MA.

J Control Release. 2012 Jan 30;157(2):224-34. doi: 10.1016/j.jconrel.2011.09.071. Epub 2011 Sep 17.

20.

A common symptom of an uncommon disease.

Sia VM, Sia DC, Yamashiro DJ, Middlesworth W, Syed M, Paudel G, Kirk R, Kigongo-Mwesezi S, Rivlin K, Leggiadro RJ.

J Pediatr Hematol Oncol. 2011 Jul;33(5):390-1. doi: 10.1097/MPH.0b013e3181ff0f14.

PMID:
21552148
21.

PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer.

Kim HK, Flexman M, Yamashiro DJ, Kandel JJ, Hielscher AH.

Biomed Opt Express. 2010 Sep 8;1(3):812-824.

22.

Vascular characterization of clear cell sarcoma of the kidney in a child: a case report and review.

Boo YJ, Fisher JC, Haley MJ, Cowles RA, Kandel JJ, Yamashiro DJ.

J Pediatr Surg. 2009 Oct;44(10):2031-6. doi: 10.1016/j.jpedsurg.2009.06.023. Review.

PMID:
19853769
23.

The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review.

Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA.

Pediatr Radiol. 2009 Jul;39(7):723-6. doi: 10.1007/s00247-009-1282-x. Epub 2009 May 9.

PMID:
19430769
24.

Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma.

Zaghloul N, Hernandez SL, Bae JO, Huang J, Fisher JC, Lee A, Kadenhe-Chiweshe A, Kandel JJ, Yamashiro DJ.

Int J Oncol. 2009 Feb;34(2):401-7.

25.

Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab.

Levy CF, Oo KZ, Fireman F, Pierre L, Bania MA, Sadanandan S, Yamashiro DJ, Glade Bender JL.

Pediatr Blood Cancer. 2009 May;52(5):669-71. doi: 10.1002/pbc.21866.

PMID:
19101996
26.

Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade.

Huang J, Bae JO, Tsai JP, Kadenhe-Chiweshe A, Papa J, Lee A, Zeng S, Kornfeld ZN, Ullner P, Zaghloul N, Ioffe E, Nandor S, Burova E, Holash J, Thurston G, Rudge J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.

Int J Oncol. 2009 Jan;34(1):79-87.

27.

Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison.

Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA.

Pediatr Radiol. 2009 Feb;39(2):155-60. doi: 10.1007/s00247-008-1062-z. Epub 2008 Nov 26.

PMID:
19034443
28.

A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis.

Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X, Shawber CJ, Kandel JJ, Yamashiro DJ, Kitajewski J.

Cancer Res. 2008 Jun 15;68(12):4727-35. doi: 10.1158/0008-5472.CAN-07-6499.

29.

Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation.

Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae JO, Huang J, Fisher J, Lefkowitch JH, Feirt N, Rudge J, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ.

Mol Cancer Res. 2008 Jan;6(1):1-9. doi: 10.1158/1541-7786.MCR-07-0101.

30.

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.

Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ; Children's Oncology Group Study.

J Clin Oncol. 2008 Jan 20;26(3):399-405. doi: 10.1200/JCO.2007.11.9230.

PMID:
18202416
31.

Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling.

Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, Eljuga L, Shawber CJ, Feirt N, Mansukhani M, Stempak D, Baruchel S, Glade Bender J, Kandel JJ, Yamashiro DJ.

Cancer Res. 2006 Apr 15;66(8):4378-84.

32.

Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.

Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B.

Mol Cancer Res. 2005 Sep;3(9):493-502.

33.

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ.

Drug Resist Updat. 2004 Aug-Oct;7(4-5):289-300. Review.

PMID:
15533766
34.

Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.

Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.

Int J Oncol. 2004 Sep;25(3):549-53.

PMID:
15289855
35.

TNP-470 promotes initial vascular sprouting in xenograft tumors.

Huang J, Frischer JS, New T, Kim ES, Serur A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ.

Mol Cancer Ther. 2004 Mar;3(3):335-43.

36.

Biomolecular markers and involution of hemangiomas.

Frischer JS, Huang J, Serur A, Kadenhe A, Yamashiro DJ, Kandel JJ.

J Pediatr Surg. 2004 Mar;39(3):400-4.

PMID:
15017560
37.

Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.

Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ.

Mol Cancer Res. 2004 Jan;2(1):36-42.

38.

A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.

Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid Bradley M, George D, Yamashiro DJ, Garvin J, Skerrett D, Bessmertny O, Wolownik K, Wischhover C, van de Ven C, Cairo MS.

Bone Marrow Transplant. 2004 Mar;33(6):613-22.

PMID:
14730337
39.

Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor.

Yokoi A, McCrudden KW, Huang J, Kim ES, Soffer SZ, Frischer JS, Serur A, New T, Yuan J, Mansukhani M, O'toole K, Yamashiro DJ, Kandel JJ.

J Pediatr Surg. 2003 Nov;38(11):1569-73.

PMID:
14614702
40.

Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma.

Kaicker S, McCrudden KW, Beck L, New T, Huang J, Frischer JS, Serur A, Kadenhe-Chiweshe A, Yokoi A, Kandel JJ, Yamashiro DJ.

Int J Oncol. 2003 Dec;23(6):1651-5.

PMID:
14612937
41.

Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor.

Yokoi A, McCrudden KW, Huang J, Kim ES, Soffer SZ, Frischer JS, Serur A, New T, Yuan J, Mansukhani M, O'Toole K, Yamashiro DJ, Kandel JJ.

Oncol Rep. 2003 Sep-Oct;10(5):1271-4.

PMID:
12883692
42.

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7785-90. Epub 2003 Jun 12.

43.

VEGF blocking therapy in the treatment of cancer.

Glade-Bender J, Kandel JJ, Yamashiro DJ.

Expert Opin Biol Ther. 2003 Apr;3(2):263-76. Review.

PMID:
12662141
44.

Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.

McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ, Middlesworth W.

J Pediatr Surg. 2003 Mar;38(3):308-14; discussion 308-14.

PMID:
12632340
45.

Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene.

Yeh A, Wei M, Golub SB, Yamashiro DJ, Murty VV, Tycko B.

Genes Chromosomes Cancer. 2002 Oct;35(2):156-63.

PMID:
12203779
46.

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11399-404. Epub 2002 Aug 12.

47.

Topotecan is anti-angiogenic in experimental hepatoblastoma.

McCrudden KW, Yokoi A, Thosani A, Soffer SZ, Kim ES, Huang J, Manley C, O'toole K, Yamashiro DJ, Kandel JJ, Middlesworth W.

J Pediatr Surg. 2002 Jun;37(6):857-61.

PMID:
12037749
48.

Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts.

Soffer SZ, Kim E, Huang J, McCrudden K, Yokoi A, Moore JT, Manley C, O'Toole K, Middlesworth W, Stolar C, Yamashiro DJ, Kandel JJ.

J Pediatr Surg. 2002 Mar;37(3):528-32.

PMID:
11877682
49.

p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.

Huang J, Soffer SZ, Kim ES, Yokoi A, Moore JT, McCrudden KW, Manley C, Middlesworth W, O'Toole K, Stolar C, Yamashiro DJ, Kandel JJ.

J Pediatr Surg. 2002 Mar;37(3):523-7.

PMID:
11877681
50.

Distinct response of experimental neuroblastoma to combination antiangiogenic strategies.

Kim ES, Soffer SZ, Huang J, McCrudden KW, Yokoi A, Manley CA, Middlesworth W, Kandel JJ, Yamashiro DJ.

J Pediatr Surg. 2002 Mar;37(3):518-22.

PMID:
11877680

Supplemental Content

Loading ...
Support Center